Nuvilex, Inc. Could Become Significant Player in the Oncology Arena With Successful Phase III Trials

NEW YORK, NY--(Marketwired - May 22, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is a diamond in the rough in the truest sense. Currently shares of the Silver Spring, Maryland, biotechnology firm can be purchased for around 0.15/share allowing investors to build an incredible position in the company for what could be a blockbuster future. Don't expect these great prices to last forever though. According to Nuvilex's COO, Dr. Gerry Crabtree, the company expects to start its pivotal Phase III trials in early 2014, so expect to start seeing news being released by the company as each piece of the trial starts to fall into place. Those who have any experience at all investing in biotech and pharmaceutical companies know the excitement generated as the news starts to unfold and the Phase III trials draw closer.

Many can probably remember the days when Dendreon Corp. lit up NASDAQ's boards with its first product, PROVENGE® (sipuleucel-T), a cancer drug approved by the U.S. Food and Drug Administration (FDA) in April 2010. By the end of the month, shares of Dendreon had reached almost $60.00/share which was a far cry from the $2.60 the company's shares hovered around while investors accumulated a position just one year prior to FDA approval.

No one is saying that Nuvilex is going to $60/share, but what could be said is the company is ideally priced for investors who are looking for that diamond in the rough, should the past be any indication of the future. If Nuvilex's Phase III trials in advanced, inoperable pancreatic cancer are successful, and we have every reason at this point to expect that they will be, then a host of potentials enter the picture for the future of the company. 

Stock House Group, a research and content development investment relations firm, contends that the Phase III trials for Nuvilex will be much like high school algebra where you knew the answer, but you still had to show your work. It is our opinion that Nuvilex's cell encapsulation technology is a "game-changer" and we feel the Phase III trials will confirm what the technology has already confirmed in two independent Phase II trials in advanced, inoperable pancreatic cancer.

In the data from those trials using encapsulated cells capable of converting the anticancer drug ifosfamide into its "cancer-killing" form, Median Survival Time and the One-Year Survival Rate were about doubled as compared to historical data for Gemzar -- the current standard and the only drug approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer. Now, it's up to Nuvilex to "show its work" to the FDA and other regulatory agencies.

The list of potential accomplishments for Nuvilex is growing if the company does, in fact, have successful Phase III trials. And, if even one or two of those potential outcomes we've outlined below is realized, it could prove to be a real "boon" for Nuvilex shareholders.

Continue reading this Article at www.stockhousegroup.com/features.

About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the press with Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research for Investors to become better informed on small cap stocks.